Ratings FUSN PHAR

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
21.4 ^USD	-0.09%		+0.38%	+122.68%

04-16	TD Cowen Downgrades Fusion Pharmaceuticals to Hold	MT
04-09	Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality